poisar

Stock

United Therapeutics Corporation UTHR

$516.70-0.37%

Overview

UTHR market data

Price History

UTHR price chart · 1M
O
515.58
H
521.29
L
514.44
C
516.70
Vol
19,575.00
Source
US equities market feed
Observed
Aug 26, 2026, 12:00 AM
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & Performance

Open
$515.58
Previous Close
$518.62
Day High
$521.29
Day Low
$514.44
52 Week High
$608.70
52 Week Low
$471.29
7 Day Return
-2.40%
30 Day Return
-1.98%
90 Day Return
-8.04%
1 Year Return
+8.06%
Daily Notional Volume
$10.1M
Latest daily bar volume multiplied by its closing price.

Valuation & Profitability

Provider-backed
P/E (TTM)
17.03
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
$27.86
Diluted earnings per share over the trailing twelve months.
Beta
0.50
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
41.6%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$302.19 – $609.35
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $22.3B · P/B 2.96 · P/S 7.08.

Company News

10 captured
United Therapeutics Announces FDA Accepted NDA For Ralinepag In Pulmonary Arterial Hypertension, With PDUFA Target Action Date Of June 24, 2027Benzinga · Aug 24, 2026, 1:28 PM
United Therapeutics Announces Full Enrollment Of TETON-PPF Study Evaluating Use Of Tyvaso Inhalation Solution For Treatment Of Progressive Pulmonary Fibrosis; Topline Data Expected In H2 Of 2027Benzinga · Aug 17, 2026, 11:11 AM
RBC Capital Maintains Outperform on United Therapeutics, Lowers Price Target to $677Benzinga · Aug 6, 2026, 5:57 PM
8-K filing — UNITED THERAPEUTICS Corp (UTHR)SEC EDGAR · Aug 5, 2026, 10:33 AM
United Therapeutics Q2 EPS $7.27 Beats $6.88 Estimate, Sales $783.300M Miss $805.645M EstimateBenzinga · Aug 5, 2026, 10:30 AM
United Therapeutics Announces Publication of ADVANCE OUTCOMES Study in The Lancet; Ralinepag Remains Investigational for PAHBenzinga · Jul 29, 2026, 10:37 AM
United Therapeutics CEO Sells $5 Million of Shares. What Does This Mean for Investors?The Motley Fool · Jul 28, 2026, 10:15 PM
JP Morgan Maintains Overweight on United Therapeutics, Raises Price Target to $687Benzinga · Jul 23, 2026, 6:47 PM
B of A Securities Maintains Neutral on United Therapeutics, Lowers Price Target to $613Benzinga · Jul 10, 2026, 6:10 PM
BETA Completes First FAA eIPP Electric Aircraft Flights, Transporting Manufactured Organs For United TherapeuticsBenzinga · Jul 10, 2026, 4:40 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock